semaglutide dopamine GLP-1 shown to decrease dopamine. Read that sentence again slowly. Not appetite. Not calories. Not “willpower.” Dopamine. That tiny little molecule sitting in the crossroads of motivation, novelty, pursuit, anticipation, movement, reward GLP-1 was approved as a

The GLP-1 medications currently approved and used in clinical practice, primarily for the treatment of type 2 diabetes and obesity, include: Semaglutide: Ozempic, Wegovy, Rybelsus Tirzepatide: Mounjaro, Zepbound Liraglutide: Victoza, Saxenda Dulaglutide: Trulicity Exenatide: Byetta, Bydureon Expanding Beyond Obesity The therapeutic potential of GLP-1s extends beyond weight management

Unique role of junctional adhesion moleculea in maintaining mucosal homeostasis in inflammatory bowel disease

there is no documented protocol for intermediate values like 3.75 mg or 11 mg, and there is nothing documented above 15 mg

Both of these drugs require repeated IV infusions and MRI scans to monitor for serious brain side effects, which, of course, adds to the overall cost and clinic time for physicians

Pernicious anemia, however, can cause major health issues like nerve damage and heart failure if left untreated

For microdosing, you want the largest draw volume possible